GlassScriptPhysician profile
Nina K Doerr
NPI 1669126769
$3,686.95
in general payments reported to CMS, 2019-2025
15 companies · $1,368 in 2025
The $1,368 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $83.94 · 2023: $1,161 · 2024: $1,074 · 2025: $1,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,598 · Education: $5.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,597.88 |
| Education | $5.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $773.30 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $753.13 | 2023-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $484.71 | 2022-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $422.10 | 2022-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $351.47 | 2023-2025 | Spravato |
| Collegium Pharmaceutical, INC. | $249.33 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $146.36 | 2025 | Caplyta |
| Abbvie INC. | $143.77 | 2023-2025 | |
| Tris Pharma INC | $112.17 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Otsuka America Pharmaceutical, INC. | $72.66 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neos Therapeutics, LP | $68.05 | 2022-2023 | Adzenys Xr-Odt |
| Vertical Pharmaceuticals, LLC | $44.06 | 2025 | Relexxii |
| Avion Pharmaceuticals | $32.13 | 2023 | Dhivy, Methylphenidate Hydrochloride |
| Vanda Pharmaceuticals INC. | $19.31 | 2025 | Fanapt |
| Lundbeck LLC | $14.40 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Doerr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.